Latest news with #PD
Daily Record
2 hours ago
- Entertainment
- Daily Record
Michael van Gerwen returns to darts stage after marriage split
Dutch star appeared in Belgium and now poised for World Series event in US Mighty Michael van Gerwen is back on the stage and ready to return to the big-time at this week's US Masters in New York. The three-times World Champion has been absent from darts for a short spell after taking time away from the game following the public announcement last month of a separation from wife Daphne. However, Van Gerwen was back on the oche on Saturday evening when taking part in a Modus exhibition in Waregem, Belgium. The 36-year-old is now poised for a comeback to the competitive PDC scene at the Word Series event at Madison Square Gardens this upcoming weekend. Van Gerwen's return will see him hunt success in the United States for a third time having won the Big Apple tournament on two previous occasions, most recently when thrashing North American Champion Jeff Smith 8-0 in 2023. The Dutchman's appearance will be hugely welcomed by his army of fans and a tilt at the fourth World Matchplay crown in Blackpool next month now on the agenda. Van Gerwen's colleague and fellow PDC pro Vincent van der Voort stated last week that his buddy is ready to go again has focused after his period away from the oche. Speaking on his Darts Draait Door Podcast, van der Voort revealed: 'He is working hard on himself and is at least training a lot again. "Of course, there is still a lot to be arranged with the divorce, but I do have the idea that the switch has been turned and that he is fully focused on his career again. "I hope to see a good Van Gerwen again within a few months. It can go fast. Will he be as eager as he was eight years ago? That is what you want to work towards.' Van Gerwen, who missed Finals night of the Premier League at London's O2 for the first time in his career this term, will rejoin the elite ahead they head across the Atlantic for the World Series event. World Champion Luke Littler and World No.1 Luke Humphries will make their first appearance since the pair's shock World Cup flop with England to headline the list of eight PDC representatives, which also includes reigning champion Rob Cross. Gerwyn Price, van Gerwen and 2019 winner Nathan Aspinall will be supplemented by Stephen Bunting, who has starred in all three World Series finals in 2025, winning the Bahrain Darts Masters and Nordic Darts Masters, while finishing runner-up at the Dutch Darts Masters. Bunting will now make his debut on American soil having won a ProTour in Leicester last week, while Australian No.1 Damon Heta also makes his first World Series appearance of the season. Alongside the US Darts Masters, the bet365 North American Championship will also take place on Saturday June 27, as the eight North American challengers compete for the coveted title and a place in this year's World Darts Championship and Grand Slam of Darts. The seventh staging of the US Darts Masters will see the eight PD stars joined by eight North American stars across a bumper weekend of action.
Metro
2 days ago
- Health
- Metro
Your earwax might be able to predict if you have Parkinson's disease
Chemical differences in people' earwax may be a telltale sign of Parkinson's that could revolutionise the fight against the disease, new research suggests. Parkinson's disease, which affects physical movement by damaging the brain, is very hard to diagnose early on. The high cost of brain scans means the only widely viable method is a specialist's evaluation of physical symptoms, which develop only after significant damage to the brain has happened. Since early treatment makes a huge difference in later quality of life, experts are keen to find other ways to detect it. The idea that people with Parkinson's give off different chemicals gained traction after credible evidence emerged that they smell noticeably different. Joy Milne, a retired Scottish nurse in her 70s with a rare condition giving her heightened smell, came forward in 2016 after noticing a distinct change in the smell of her late husband when he began to develop the disease. She was able to guess 100% correctly whether randomly picked items of clothing had belonged to someone with Parkinson's. Since then, early research proved promising for a skin swab test that involves running a cotton bud along the back of the neck. Scientists believe people with Parkinson's have different levels of certain compounds in their sebum, an oily substance produced by glands in the skin. Now another potential method building on this may have been discovered by scientists from Zhejiang University in China. Since earwax is made mostly of sebum, they decided to analyse samples from around 200 people who were known to be living with or without Parkinson's. Data on the chemical make-up of their earwax was into an algorithm that correctly guessed whether an individual had Parkinson's or not 94% of the time. This was based on the levels of four specific types of compounds, which were significant regardless of each person's age and lifestyle. Two of them, ethylbenzene & 4-ethyltoluene, are known to be signs of inflammation in the brain previously linked to Parkinson's. More Trending Another was pentanal, which has been linked to accumulations of protein clumps in patients' brains that are a telltale sign of Parkinson's. The study's authors said 'early diagnosis and treatment are crucial' for treatment. It's hoped their model could lead to a chemical testing device that could be easily distributed to clinics. 'Further enhancements to the diagnostic model could pave the way for a promising new PD diagnostic solution and the clinical use of a bedside PD diagnostic device.' Get in touch with our news team by emailing us at webnews@ For more stories like this, check our news page.
Yahoo
13-06-2025
- Yahoo
Round Rock prepares for Juneteenth celebration 1 year after deadly shooting
The Brief It has been nearly one year since the deadly shooting at Round Rock's Juneteenth celebration RRPD have arrested seven people in connection with the shooting Round Rock's mayor said there will be lots of police presence to help with safety ROUND ROCK, Texas - It's been nearly one year since the mass shooting at Round Rock's Juneteenth celebration. One year ago, a shooting at the Juneteenth celebration between two groups over a social media post injured multiple people and killed two mothers, Lyndsey Vicknair and Ara Duke. They were caught in the crossfire. Nearly 10 people have been arrested in connection with the shooting. What they're saying On Wednesday afternoon, Old Settlers Park was still quiet as crews set up the stage for this year's Juneteenth celebration. For Round Rock Mayor Craig Morgan, it does not go unnoticed that in this year's celebration, there is also a sense of heaviness. "It's something that you'll never forget, you know, serving in this seat," said Morgan. "The last thing you want is to have a loss of life when you're the mayor." This weekend, Mayor Morgan feels confident about bringing the celebration back. "I trust our PD more than anything," said Morgan. "I know what kind of work they do, just kind of with like the investigations. I know they worked tirelessly and still are working tirelessly." Police have arrested seven people in connection with the shooting. "We're not going to stop," said Round Rock Police Chief Allen Banks. "This case just doesn't stop because we have those seven in custody. Anybody that was involved in this tragic incident will be held accountable, and we won't stop until we have everybody that was involved." Banks said attendees can expect to see his officers at Old Settlers. "We'll be out, our presence will be known," said Banks. "We'll be out there with the crowd and walking around the event. At 7:30 p.m. on Saturday, June 14, the celebration will pause for a video to remember the victims, followed by two beams of light pointing to the heavens. "We're not going to let evil stop what we're doing," said Banks. "We're a great community, we're a great city with great events and our presence will be known, and again, anybody that decides they want to come out and disrupt a great family fun event, we're going to be there." The celebration will be moved to Yonder's Point at Old Settler's Park due to construction. It begins on Friday, June 13, with a barbecue. The Source Information from interviews conducted by FOX 7 Austin's Lauren Rangel
Los Angeles Times
11-06-2025
- Health
- Los Angeles Times
Parkinson's Disease: What We Know and Where Treatment Is Headed
Parkinson's disease (PD) is more than a movement disorder—it's a neurological condition that reshapes the lives of patients and families. Parkinson's affects both motor and non-motor functions so its impact is broad and multifaceted. While tremors and stiffness may be the most visible signs, PD also brings a wide range of symptoms that impact thinking, mood and overall functioning. Common symptoms are bradykinesia, rigidity, tremor, postural instability, sleep disturbances and mood changes. As science digs deeper into this condition, hope grows for more precise, effective and compassionate care. Parkinson's disease is defined by the gradual loss of dopamine producing neurons in a part of the brain called the substantia nigra. This dopamine deficiency disrupts the brain circuits responsible for smooth and coordinated movements, leading to hallmark motor symptoms: resting tremor, muscle rigidity, slowness of movement (bradykinesia) and postural instability [1] [3] [5]. These are the most common Parkinson's disease symptoms targeted by treatment. The hallmark motor symptoms encompass a range of movement symptoms and movement related symptoms that affect daily functioning. Postural instability often results in balance problems making coordination and stability difficult for patients. In addition to resting tremor, muscle rigidity, slowness of movement (bradykinesia) and postural instability, other motor symptoms such as freezing of gait and difficulty with fine motor tasks may also occur. Collectively these are referred to as PD symptoms, the clinical features of Parkinson's disease. But PD isn't just about what the body can or can't do—it's also about what the brain feels. Long before a tremor appears many patients experience non-motor symptoms: Parkinson's symptoms, both motor and non-motor, can develop gradually and vary significantly between individuals. These symptoms can be easy to overlook or misattribute, often delaying diagnosis. According to a 2008 review, clinicians rely on a detailed medical history and physical examination to distinguish PD from other parkinsonian syndromes [1], while a 2020 JAMA review emphasizes the role of dopamine transporter (DAT) imaging and clinical expertise in diagnosis and staging [5]. Parkinson's is diagnosed primarily through evaluation of medical history and clinical examination, as there is no definitive blood test or brain scan for confirmation. So, what causes Parkinson's disease? The short answer: it's complicated. Most cases are considered idiopathic—meaning no single cause is identified—but multiple factors seem to converge. Both genetic and environmental factors are recognized as major contributors to the development of Parkinson's disease. Genetic contributions are increasingly recognized, with mutations in genes like LRRK2, PARK7 and SNCA playing a role [2]. Genetic mutations in these and other genes can influence disease development, sometimes interacting with environmental exposures. But genes don't tell the whole story. Environmental exposures, such as pesticide use or heavy metals, also contribute, especially in individuals with underlying vulnerabilities. At the cellular level PD is defined by several overlapping pathological processes: The loss of dopamine producing neurons in the substantia nigra involves the degeneration and death of specific brain cells and nerve cells which underlies the motor and non-motor symptoms of Parkinson's disease. These mechanisms interact like a feedback loop—fueling one another and accelerating neurodegeneration. This complex interplay drives the disease process, shaping both the progression and development of Parkinson's disease. Parkinson's disease affects more than 10 million people worldwide, with incidence rising sharply with age—especially after 60 [11]. Most Parkinson's disease cases are idiopathic and occur in older adults, with the majority of diagnoses in people over 60. However, early onset cases, known as early onset PD, can develop before age 50 and may differ in disease progression, diagnosis and treatment compared to typical cases. Men are more frequently affected than women, and rural living, well water exposure and pesticide contact are established risk factors. On the other hand, researchers have also identified protective factors. Regular caffeine consumption, moderate nicotine exposure and consistent physical activity may lower PD risk. Though not fully understood, these factors may influence inflammation, neuroplasticity or dopamine metabolism. There's no single test for Parkinson's, which makes early and accurate diagnosis a clinical challenge. Physicians typically rely on: In advanced diagnostic settings a spinal tap (lumbar puncture) may be performed to collect spinal fluid for biomarker analysis, such as detecting abnormal alpha-synuclein proteins. New frontiers are expanding diagnostic accuracy. Machine learning algorithms are being trained to analyze voice patterns, gait dynamics and digital biomarkers. AI-enhanced diagnostics and bioinformatics platforms are also being developed to detect early inflammatory signals before motor symptoms emerge [10]. Autonomic testing, including monitoring for blood pressure changes, may be used to assess non-motor symptoms. Distinguishing Parkinson's disease from other syndromes is crucial, with multiple system atrophy being an important differential diagnosis due to overlapping symptoms but differing disease progression and treatment responses. While there's no cure for PD, treatment can significantly improve quality of life. The primary goal of therapy is to manage symptoms and help patients maintain independence. Medications: Medication is different from surgery and should be discussed with a doctor. Dopaminergic medications can cause orthostatic hypotension and low blood pressure so monitoring is important. Non-medication is equally important: PD can also affect mood, behavior and cognition. Managing neuropsychiatric symptoms like depression or hallucinations requires a nuanced approach, including SSRIs, atypical antipsychotics and cognitive behavioral therapy. The Parkinson's Foundation is a key player in advancing research and treatment for Parkinson's disease. As the disease progresses many patients develop cognitive impairment, from mild forgetfulness to full blown Parkinson's Disease Dementia (PDD). These symptoms can overlap with or mimic Dementia with Lewy Bodies (DLB) (also known as Lewy body dementia) and Progressive Supranuclear Palsy (PSP) and other disorders within the spectrum of atypical parkinsonism, so accurate diagnosis is critical. A 2025 study compared cognitive trajectories across these syndromes and emphasized the need for tailored care and better biomarkers to distinguish between them. Inflammation is no longer seen as just a consequence of PD—it may be the cause. Recent studies, including a 2025 paper using machine learning and bioinformatics, have identified new inflammatory markers that could help with early diagnosis [10]. Ongoing Parkinson's research is key to finding new biomarkers, better treatments and a are also finding potential therapeutic targets. For example, UPS10, a protein that blocks α-synuclein degradation, may be a way to stop disease progression [8]. And lipid metabolism pathways open up metabolic interventions. These therapeutic strategies aim to modify the disease process to slow or stop progression. This is driving personalized medicine where treatment is based on a patient's genetic, metabolic or inflammatory profile. And the average life expectancy for most people with PD is the same as the general population thanks to research and care. Parkinson's disease is still a challenge for patients, caregivers and clinicians. But it's also a global research effort to understand the onset, progression and treatment of the disease. As we understand the interplay of genetics, environment and inflammation the future of PD looks more precise and hopeful. Until then a multidisciplinary approach – medication, therapy and emotional support – is the foundation of good care. [1] Jankovic J. (2008). Parkinson's disease: clinical features and diagnosis. Journal of neurology, neurosurgery, and psychiatry, 79(4), 368–376. [2] Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. Lancet (London, England), 386(9996), 896–912. [3] Marino, B. L. B., de Souza, L. R., Sousa, K. P. A., Ferreira, J. V., Padilha, E. C., da Silva, C. H. T. P., Taft, C. A., & Hage-Melim, L. I. S. (2020). Parkinson's Disease: A Review from [4] Pathophysiology to Treatment. Mini reviews in medicinal chemistry, 20(9), 754–767. [5] Balestrino, R., & Schapira, A. H. V. (2020). Parkinson disease. European journal of neurology, 27(1), 27–42. [6] Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and Treatment of Parkinson Disease: A Review. JAMA, 323(6), 548–560. [7] Qin, B., Fu, Y., Raulin, A. C., Kong, S., Li, H., Liu, J., Liu, C., & Zhao, J. (2025). Lipid metabolism in health and disease: Mechanistic and therapeutic insights for Parkinson's disease. Chinese medical journal, 10.1097/CM9.0000000000003627. Advance online publication. [8] Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. Lancet (London, England), 397(10291), 2284–2303. [9] Anisimov, S., Takahashi, M., Kakihana, T., Katsuragi, Y., Sango, J., Abe, T., & Fujii, M. (2025). UPS10 inhibits the degradation of α-synuclein, a pathogenic factor associated with Parkinson's disease, by inhibiting chaperone-mediated autophagy. The Journal of biological chemistry, 110292. Advance online publication. [10] Halli-Tierney, A. D., Luker, J., & Carroll, D. G. (2020). Parkinson Disease. American family physician, 102(11), 679–691. [11] Li, Y., Jia, W., Chen, C., Chen, C., Chen, J., Yang, X., & Liu, P. (2025). Identification of biomarkers associated with inflammatory response in Parkinson's disease by bioinformatics and machine learning. PloS one, 20(5), e0320257. [12] Tysnes, O. B., & Storstein, A. (2017). Epidemiology of Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 124(8), 901–905.
Yahoo
11-06-2025
- Business
- Yahoo
Niagen Bioscience to Participate in the BIO 2025 International Convention
LOS ANGELES, June 11, 2025--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its participation in the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world's largest and most influential biotechnology event, convening more than 20,000 global leaders from across the life sciences ecosystem, including biopharma, academia, investment, and government. The convention provides companies with unique access to a partnering forum. By participating in BIO 2025, Niagen Bioscience is seeking to initiate discussions with prospective partners to support the development and monetization of its emerging drug product candidates. Niagen Bioscience is arranging a full slate of one-on-one meetings with pharmaceutical companies focused on neurodegenerative diseases, including Parkinson's disease (PD), Ataxia Telangiectasia (AT), among others, and plans to have partnering discussions. Attending from Niagen Bioscience's executive leadership team will be Ozan Pamir, CFO, Andrew Shao, Ph.D., Senior Vice President of Global Scientific and Regulatory Affairs, and Yasmeen Nkrumah-Elie, Ph.D., Senior Global Director of External Research. To request a meeting with the team, please reach out to the Company through the BIO Partnering platform at or email niagenir@ For additional information on Niagen Bioscience, visit About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. †Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the preliminary status of the companies plans, strategies, and expectations concerning the pursuit of partnerships to develop and commercialize pharmaceutical candidates for the treatment of neurodegenerative diseases; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. View source version on Contacts Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Niagen Bioscience Investor Relations Contact: ICR, LLCReed Anderson(646) 277-1260Stephanie Carrington(646) 277-1282niagenir@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
